Have we been adequately providing the information required after insurance coverage for hereditary breast and ovarian cancer care in Japan?

Abstract

　The rate of providing hereditary breast and ovarian cancer (HBOC) information in regular practice has increased since its insurance coverage was introduced in April 2020, therefore its implementation rate is essential. We examined 188 patients who underwent surgery for primary breast cancer at our hospital between April 2020 and December 2022 and were eligible for genetic testing (GT) under the insurance system. The information provision rate was 62.2%, and this rate decreased with increasing age. About half (49.6%) of the cases had only one eligible item for GT, and the rate among those who did not have a GT was significantly lower for those aged > 40 years. Furthermore, after receiving information, 65% of the cases proceeded to genetic counseling, and 96% of these individuals underwent GT. These findings highlight the need for improved information provision to patients with only one eligible item. Additionally, increasing the rate of information provision, especially for patients aged > 40 years, is crucial.